Gland Pharma receives USFDA approval for its generic Edaravone injection, used to treat amyotrophic lateral sclerosis (ALS). The company expects to launch the product through its marketing partner within FY25.
New Delhi, May 7 (PTI) Gland Pharma Ltd on Tuesday said it has received approval from the US health regulator for its generic Edaravone injection to treat amyotrophic lateral sclerosis.
The approval by the US Food and Drug Administration (USFDA) is for Edaravone injection of strengths 30 mg/100 ml and 60 mg/100 ml single-dose bags, Gland Pharma said in a regulatory filing.
The company expects to launch the product through its marketing partner within FY25, it added.
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Radicava injection, 30 mg/100 ml and 60 mg/100 ml of Mitsubishi Tanabe Pharma Corporation, it added.
Edaravone injection is used to treat amyotrophic lateral sclerosis (ALS), a condition in which the nerves that control muscle movement slowly die, causing the muscles to shrink and weaken.
It had sales of approximately USD 19 million in the US for the 12 months ended January 2024, Gland Pharma said citing IQVIA data.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback